by andre | Jul 27, 2026 | KoreFeed
SARCOMATRIX THERAPEUTICS CORP. FOR IMMEDIATE RELEASE Sarcomatrix Applies SarcoVista™ Translational Modeling to First-in-Human Dose Selection for S-969 The preclinical-stage company is using its proprietary modeling platform to inform the starting dose and escalation...
